Efficacy and safety of fruquintinib plus sintilimab in third-line treatment of metastatic colorectal cancer: A single-center experience

doi:10.4251/wjgo.v18.i6.117101

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 6

This Article

(14)

(17)

(0)

(23)

(500)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Jun 15, 2026; 18(6): 117101
Published online Jun 15, 2026. doi: 10.4251/wjgo.v18.i6.117101

Table 2 Treatment regimens

Treatment regimens
mFOLFOX6 + Bev	Oxaliplatin 100 mg/m² on day 1, leucovorin 400 mg/m² on days 1-2, and fluorouracil 2400 mg/m² once over 46 hours on days 1-3, bevacizumab 5 mg/kg on day 1
OXA + RTX	Oxaliplatin 130 mg/m² on day 1, raltitrexed 3 mg/m² on day 1
mFOLFOX6 + Cet	Oxaliplatin 100 mg/m² on day 1, leucovorin 400 mg/m² on days 1-2, and fluorouracil 2400 mg/m² once over 46 hours on days 1-3, cetuximab 500 mg/m² on day 1
XELOX	Oxaliplatin 130 mg/m² on day 1 and capecitabine 1000 mg/m² twice daily on days 1-14
XELOX + Bev	Oxaliplatin 130 mg/m² on day 1, capecitabine 1000 mg/m² twice daily on days 1-14, bevacizumab 7.5 mg/kg on day 1
CPT-11 + RTX	Irinotecan 200 mg/m² on day 1, raltitrexed 3 mg/m² on day 1
CPT-11 + RTX + Bev	Irinotecan 200 mg/m² on day 1, raltitrexed 3 mg/m² on day 1, bevacizumab 7.5 mg/kg on day 1
Fruquintinib + sintilimab	Fruquintinib 3 mg once daily on days 1-21, sintilimab 200 mg on day 1

mFOLFOX6: Oxaliplatin + leucovorin + fluorouracil; Bev: Bevacizumab; OXA: Oxaliplatin; RTX: Raltitrexed; Cet: Cetuximab; XELOX: Oxaliplatin + capecitabine; CPT-11: Irinotecan.

Full Size Table

Citation: Pan J, Li P, Zhao Y, Zhou YH, Zhao Y, Zhang TL, Chen YT, Chu XY. Efficacy and safety of fruquintinib plus sintilimab in third-line treatment of metastatic colorectal cancer: A single-center experience. World J Gastrointest Oncol 2026; 18(6): 117101
URL: https://www.wjgnet.com/1948-5204/full/v18/i6/117101.htm
DOI: https://dx.doi.org/10.4251/wjgo.v18.i6.117101

Pan J, Li P, Zhao Y, Zhou YH, Zhao Y, Zhang TL, Chen YT, Chu XY. Efficacy and safety of fruquintinib plus sintilimab in third-line treatment of metastatic colorectal cancer: A single-center experience. World J Gastrointest Oncol 2026; 18(6): 117101 [DOI: 10.4251/wjgo.v18.i6.117101]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.